
Krsnaa Diagnostics Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company targets a sustained revenue growth of approximately 30% CAGR for FY24 and FY25, excluding the Rajasthan project.
- FY24 expects around Rs. 600 crores revenue with Rs. 180-200 crores per quarter in FY25.
- New projects in Odisha, Assam, Maharashtra CT, Himachal Pradesh, and BMC are key growth contributors for FY25.
- Rajasthan project revenue potential has revised upward to Rs. 300 crores due to district reorganization, though commercialization may shift to FY25.
- Additional tenders, including a large radiology tender in Andhra Pradesh and others in the pipeline, are expected to add Rs. 140 to Rs. 200 crores top-line by FY25 and beyond.
- Mature centers and existing projects also expected to grow at 8-30%, supporting overall 30% growth trajectory.
- B2C business segment gradually scaling up with positive early traction.
See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript from the earnings call on page 22 and surrounding pages does not mention any current or planned fundraising through debt or equity.
- As of September 30, 2023, the company holds a gross debt of Rs. 109 crores but maintains a net debt-free status with Rs. 236 crores in cash and cash equivalents.
- No specific references were made to raising additional funds via debt or equity in the near future.
- The management focuses on organic growth through existing projects and new tenders without highlighting fundraising plans.
- Any significant capital expenditures, such as on Rajasthan, are currently minimal and expensed rather than capitalized.
- For inquiries, investors are encouraged to contact the Investor Relations Team, but no fundraising announcements were disclosed in this call.
See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.
Capex plans
Yes- The company is investing in setting up new laboratories and collection centers as part of various Public-Private Partnership (PPP) projects across states like Assam, Odisha, Maharashtra (CT project), Himachal Pradesh, and Mumbai (BMC project).
- They have invested in expanding the Mumbai lab to support the rapid operationalization of around 462 centers under the BMC contract.
- Ongoing capex includes setting up Radiology centers, Pathology labs, and collection centers which require upfront costs for equipment, manpower, interiors, infrastructure, and logistics.
- While initial quarters incur higher expenses due to front-loaded investments, these centers typically mature after 2-3 years, leading to improved margins.
- No significant capitalization has been made for the Rajasthan project yet; only operational expenses have been incurred and expensed out.
- They expect capex costs to reduce over time as projects mature and ramp up operations, contributing positively to margins going forward.
Track Krsnaa Diagnostics — get its next earnings analysis in your feed
How does Krsnaa Diagnostics rank vs peers in Healthcare Services?
Pro featureHow does Krsnaa Diagnostics rank in Healthcare Services?
Compare Krsnaa Diagnostics against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.